


110  
**Beth Israel Deaconess  
Medical Center**

Director, Biotherapeutics Development Lab  
Division of Hematology-Oncology



0300  
**Harvard Medical School**  
CC

**Richard P. Junghans, PhD, MD**

Beth Israel Deaconess Medical Center  
Harvard Institutes of Medicine  
4 Blackfan Circle, #403 • Boston, MA 02215 USA  
617 432-7004 • FAX 617 432-7007  
email: junghans@hms.harvard.edu

Assistant Professor of Medicine  
Member, Harvard Institute of Human Genetics

October 22, 2003

Director of The United States Patent and Trademark Office  
United States Patent and Trademark Office  
Washington, D.C. 20231

**RE: "Antibodies as Chimeric Effector Cell Receptors against Tumor Antigens" #10/006,773.**

To Whom It May Concern:

As requested, attached is a substitute computer readable form (CRF) copy of the "Sequence Listing". An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification with a copy of the 7/24/2003 "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acids Sequence Disclosures" for application No. 10/006,773. The data contained in the CRF are identical to the written sequence and contains no new matter. The late fee of \$210.00 may be charged to my Visa Card Account shown on the attached USPTO Credit Card Payment Form.

Please call my administrative assistant, Cassandra Carter, with any questions.

Thank you.

Sincerely,

Richard P. Junghans, Ph.D., M.D.

Encl.

RPJ/cc